Mizuho Securities Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences (MBX) with a $91.00 price target. This follows UBS's July 24 report, which also maintained a Buy rating and set a $90.00 target for the healthcare stock.
Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Evolus, and Arcutis Biotherapeutics. According to TipRanks, Ear has an average return of 6.1% and a 43.00% success rate on recommended stocks.
In a report released on July 24, UBS also reiterated a Buy rating on the stock with a $90.00 price target.